Despite their diverse backgrounds, our researchers are remarkably alike in their relentless curiosity, their fearless approach to collaboration, and a results-driven, entrepreneurial streak that has inspired many of them to launch startups.
At the Biointerfaces Institute, the combination of talent, facilities and culture of interdisciplinary research is igniting new discoveries and speeding the delivery of high-impact technologies to the world.
Since 2012, discoveries from BI research labs has resulted in over 130 inventions and 85 issued patents. Many of these technologies are being commercialized by existing companies or by startup companies launched by BI researchers.
EVOQ Therapeutics was formed in 2016 to develop new vaccine technologies for cancers and based on research from James Moon and Anna Schwendeman.Learn More
Elegus focuses on Kevlar-based nanomaterials to produce the next generation of battery separators. The materials were developed in Nick Kotov’s lab.Learn More
Green Mark was formed in 2016 to commercialize biopolymer materials for dental and medical applications. The application of these nanoparticles in tooth decay stems from work in Joerg Lahann’s lab.Learn More
Computer vision neural network enabling material sensing within optical sensors including LIDAR and camerasLearn More
Startup company based on research in Anish Tuteja's research groupLearn More
Akadeum Life Sciences
Since 2014, Akadeum Life Sciences develops microbubbles-based technologies to enhance cell separation. The technologies are based on research in John Younger’s lab while he was at BI.Learn More
Labyrinth Biotech is develop liquid biopsy technologies to impact the life cycle management of cancer. The technology was developed in the research lab of Dr. Sunitha Nagrath.Learn More
Founded in 2013, HygraTek works on membrane and coating solutions that are based on technologies developed in Anish Tuteja’s research lab.Learn More
Development of the ASX-100 neutrophil targeting platform to treat significant unmet medical needsLearn More
PHASIQ’s two-phase platforms enable multiplexed immunoassays for protein diagnostics and derive from research in Shu Takayama’s research group.Learn More